$AMGN

Generating a unique summary for AMGN…

AI-generated for information only — not investment advice.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Institutions hold 85.18% · insiders 0.23% · 4,041 institutions

Consensus score 2.65 (1 = strong buy, 5 = sell) · mean target 396.70

• OppenheimerOutperformmain2026-10-23
• BarclaysEqual-Weightmain2026-10-21
• GuggenheimNeutralmain2026-10-13
• BMO CapitalMarket Performmain2026-10-12
• Wells FargoEqual-Weightmain2026-10-12
• UBSBuymain2026-10-09
• RBC CapitalOutperformmain2026-10-08
• Cantor FitzgeraldNeutralmain2026-10-08
• Truist SecuritiesHoldmain2026-10-07
• Morgan StanleyEqual-Weightmain2026-10-07

Next report: 2026-11-03

• 10-QPeriodic Financial Reports2026-08-05Open
• 8-KCorporate Changes & Voting Matters2026-08-04Open
• 8-KCorporate Changes & Voting Matters2026-07-31Open
• 11-KAnnual report of employee stock purchase2026-06-11Open
• 8-KCorporate Changes & Voting Matters2026-05-20Open
• 8-KCorporate Changes & Voting Matters2026-05-19Open
• 10-QPeriodic Financial Reports2026-05-01Open
• 8-KCorporate Changes & Voting Matters2026-04-30Open
• 8-KCorporate Changes & Voting Matters2026-04-22Open
• DEFA14AProxy Statements2026-04-21Open

• Amgen’s Imdelltra Cut Lung Cancer Deaths by 58%. Is It Already in the Stock?

  Amgen (AMGN:NASDAQ) put numbers on its biggest lung cancer win yet on Saturday, Oct. 24.

  Sat, 24 Oct 2026 18:21:40 +0000

• Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

  Amgen trades at a lower valuation multiple, but Johnson & Johnson's fortress balance sheet and stronger free cash flow tell a different story about financial resilience.

  Sat, 24 Oct 2026 16:31:01 +0000

• IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

  Amgen (NASDAQ:AMGN) today announced landmark interim Phase 3 results showing that IMDELLTRA® (tarlatamab-dlle) in combination with AstraZeneca's IMFINZI® (durvalumab) reduced the risk of death by 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC) (hazard ratio [HR]: 0.42; 95% confidence interval [CI]: 0.32, 0.54; P < 0.001) at a median follow-up of approximately 16 months. The DeLLphi-305 study found that IMDELLTRA in combination with durvalumab extend

  Sat, 24 Oct 2026 14:30:00 +0000

• Amgen (AMGN) Reports Positive Phase 3 TEZSPIRE Results In Eosinophilic Esophagitis

  Amgen (NasdaqGS:AMGN) and AstraZeneca reported positive full Phase 3 results for TEZSPIRE in eosinophilic esophagitis (EoE). The Phase 3 trial showed significant and clinically meaningful improvements in EoE symptoms and endoscopic endpoints sustained through one year. Investigators reported a favorable safety profile for TEZSPIRE in this EoE study population of patients with limited treatment options. The TEZSPIRE Phase 3 EoE data lands alongside wider findings from our research on Amgen's...

  Sat, 24 Oct 2026 02:14:40 +0000

• Here's Why Amgen (AMGN) Fell More Than Broader Market

  Amgen (AMGN) closed at $439.26 in the latest trading session, marking a -1.79% move from the prior day.

  Fri, 23 Oct 2026 20:50:02 +0000

• At Amgen, Sustainability Is A Companywide Commitment

  Amgen integrates sustainability goals in every part of its business with a holistic and innovative approach to manufacturing.

  Fri, 23 Oct 2026 12:30:37 +0000

• Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

  Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

  Thu, 22 Oct 2026 22:15:02 +0000

• Amgen (AMGN) Gains As Market Dips: What You Should Know

  Amgen (AMGN) closed at $447.28 in the latest trading session, marking a +2.04% move from the prior day.

  Thu, 22 Oct 2026 21:00:02 +0000